Myrtle Potter BA

Myrtle Potter is one of America’s foremost healthcare leaders and innovators. She has dedicated three decades of service and leadership to America’s most successful global healthcare companies. She has leveraged her vast experience with large pharmaceutical, biotechnology, consumer health, medical device, and medical services companies to serve the needs of patients and consumers worldwide.

Myrtle is the founder and CEO of Myrtle Potter & Company, LLC, a global life science advisory firm that was started in 2005. The firm’s clients include pharmaceutical, biotech, medical services, medical device and healthcare media companies. Myrtle Potter & Company has earned a reputation for devising novel strategies to increase the value of prescription drug brands and prescription drug portfolios. Myrtle Potter & Company also advises venture capitalists, investment bankers, private equity firms and government regulatory bodies.

Myrtle was president and chief operating officer of Genentech, Inc. where, from 2000 to 2005, she helped steer the company through one of the most successful periods in its history. Genentech achieved record sales and earnings growth during each of the five years she led the company and sales grew more than five-fold to over $5 billion over the same period. Under her leadership, the company launched seven breakthrough products including the blockbuster cancer treatment Avastin™, Xolair™, a novel treatment for severe allergic asthma. During her full tenure, she served on the Executive Committee of the Company and co-chaired the Product Portfolio Committee which made all “go/no-go” decisions for Genentech’s drug pipeline.